McCormick –The spice maker beat estimates by a penny with fourth quarter profit of $1.20 per share, excluding certain items, but gave a softer than expected outlook for the new fiscal year due to higher marketing costs.
Biogen Idec–The drug maker earned $2.34 per share, excluding certain items, for the fourth quarter, compared to estimates of $2.28. Biogen was helped by surging sales of its multiple sclerosis treatment Tecfidera.
EMC Corp–The computer storage products company reported fourth quarter profit of 60 cents per share, one cent above estimates. But EMC gave weaker than expected guidance for 2014.
Tupperware Brands–Tupperware fell three cents short of estimates with fourth quarter profit of $1.81 per share, with revenue also below consensus. The company is also forecasting current quarter sales down one to three percent, with full year sales flat to up two percent.
AT&T—The telecom giant beating estimates by three cents with fourth quarter earnings of 53 cents per share, excluding certain items. AT&T did report slower wireless subscriber growth than analysts were anticipating.
Yahoo —The Internet giant earned 46 cents per share for the fourth quarter, excluding certain items, beating estimates by eight cents. However, online ad prices fell during the fourth quarter, which analysts say usually sees stronger pricing.
Electronic Arts–EA reported fiscal third quarter profit of $1.26 per share, beating estimates by three cents. However, revenue was shy of estimates, and the video game maker also lowered its 2015 revenue forecast. New consoles such as the Xbox One and the PlayStation 4 have impacted sales of EA's games designed for older game machines.
VMWare–The software maker was ahead of estimates by a penny with fourth quarter profit of $1.01 per share, following a preliminary report last week which exceeded prior estimates by a wide margin.
Cirrus Logic–The company reported third quarter profit of 89 cents per share, excluding certain items, 12 cents above estimates. Revenue was also ahead of estimates, but the chip maker issued a current quarter revenue forecast that was well below forecasts. Cirrus is being impacted by selling products with lower average selling prices than it had previously.
Amgen–The biotech company beat estimates by 14 cents with fourth quarter earnings of $1.82 per share, excluding certain items. Revenue exceeded estimates as new product sales grew and the company gained full control of rheumatoid arthritis drug Enbrel from former partner Pfizer.
Hanesbrands–CEO Richard Noll said the apparel maker is now in a better position to return cash to shareholders, as the company raised its dividend by 50 percent to 30 cents per share.
T-Mobile–The mobile carrier's shares could be pressured by a Dow Jones report which said Justice Department officials are skeptical about a possible acquisition of T-Mobile by rival Sprint, due to antitrust concerns.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at email@example.com